ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Neumora Therapeutics Inc

Neumora Therapeutics Inc (NMRA)

10.00
0.11
(1.11%)
Closed June 12 4:00PM
10.00
0.00
( 0.00% )
Pre Market: 7:10AM

Professional-Grade Tools, for Individual Investors.

Key stats and details

Current Price
10.00
Bid
9.72
Ask
12.00
Volume
-
0.00 Day's Range 0.00
8.82 52 Week Range 21.00
Market Cap
Previous Close
10.00
Open
-
Last Trade
Last Trade Time
-
Financial Volume
-
VWAP
-
Average Volume (3m)
588,994
Shares Outstanding
158,886,101
Dividend Yield
-
PE Ratio
-6.73
Earnings Per Share (EPS)
-1.48
Revenue
-
Net Profit
-235.93M

About Neumora Therapeutics Inc

Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, ... Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; NMRA-266 for the treatment of schizophrenia and other neuropsychiatric disorders; NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Show more

Sector
Biological Pds,ex Diagnstics
Industry
Biological Pds,ex Diagnstics
Headquarters
New Castle, Delaware, USA
Founded
1970
Neumora Therapeutics Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker NMRA. The last closing price for Neumora Therapeutics was $10. Over the last year, Neumora Therapeutics shares have traded in a share price range of $ 8.82 to $ 21.00.

Neumora Therapeutics currently has 158,886,101 shares outstanding. The market capitalization of Neumora Therapeutics is $1.59 billion. Neumora Therapeutics has a price to earnings ratio (PE ratio) of -6.73.

NMRA Latest News

Neumora Therapeutics Announces Initiation of Phase 2 Study of Navacaprant in Bipolar Depression

Potential to alleviate unmet need associated with depressed mood and anhedonia in bipolar depression; navacaprant has demonstrated the ability to improve these symptoms in MDD in a Phase 2 study...

Neumora Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

On-track to report topline Phase 3 data from KOASTAL-1 study with navacaprant in MDD; guidance narrowed to fourth quarter of 2024 Multiple clinical study initiations planned in second quarter of...

Neumora Therapeutics to Participate in Upcoming Conferences in May

WATERTOWN, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven clinical...

Neumora Therapeutics Announces Clinical Hold of Phase 1 NMRA-266 Study

WATERTOWN, Mass., April 15, 2024 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven...

Neumora Therapeutics to Participate at Stifel 2024 Virtual CNS Days

WATERTOWN, Mass., March 13, 2024 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.15-1.4778325123210.1510.69.5645111710.03720039CS
40.343.519668737069.6610.68.954678759.73843801CS
12-3.93-28.212491026613.9314.958.8258899411.04111631CS
26-2.95-22.779922779912.95218.8248723613.14112396CS
52-6.5-39.393939393916.5218.8243731212.83849057CS
156-6.5-39.393939393916.5218.8243731212.83849057CS
260-6.5-39.393939393916.5218.8243731212.83849057CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
NCINeo Concept International Group Holdings Ltd
$ 1.05
(60.89%)
12.55M
LGHLWLion Group Holding Ltd
$ 0.0098
(44.12%)
1.05M
LGVNLongeveron Inc
$ 2.40
(32.60%)
7.19M
BRTXBioRestorative Therapies Inc
$ 1.66
(22.96%)
2.09M
DUOFangDD Network Group Ltd
$ 0.7369
(20.80%)
3.41M
IONMAssure Holdings Corporation
$ 0.2496
(-51.35%)
857.72k
CARACara Therapeutics Inc
$ 0.501
(-26.27%)
43.25k
APYXApyx Medical Corporation
$ 1.24
(-20.01%)
243
NAVINavient Corporation
$ 11.70
(-19.14%)
1
MTENMingteng International Corporation Inc
$ 3.90
(-18.58%)
2
NCINeo Concept International Group Holdings Ltd
$ 1.05
(60.89%)
12.55M
LGVNLongeveron Inc
$ 2.40
(32.60%)
7.19M
TSLLDirexion Daily TSLA Bull 2X Trust ETF
$ 8.51
(12.72%)
5.33M
DUOFangDD Network Group Ltd
$ 0.7369
(20.80%)
3.41M
TSLATesla Inc
$ 188.84
(6.51%)
2.97M

Your Recent History

Delayed Upgrade Clock